JonesResearch downgraded Chimerix (CMRX) to Hold from Buy with an $8.55 price target after Jazz Pharmaceuticals (JAZZ) announced a deal to acquire the company for $8.55 per share or $935M in cash.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMRX:
- Strategic Acquisition and NDA Submission Boost Chimerix’s Market Potential
- Cautious Outlook on Chimerix Amid Acquisition and Uncertainties in Drug Approval
- Chimerix downgraded to Hold from Buy at Jefferies
- CrowdStrike reports Q4 beat, Jazz to acquire Chimerix: Morning Buzz
- Hold Rating Issued Amidst Chimerix Acquisition by Jazz Pharmaceuticals